Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Can Recursion accelerate the time frame for drug discovery? Last year, Recursion announced that tech giant Nvidia invested $50 million into its operations. Together, the businesses are working on drug ...
AI-infused drug developer Recursion Pharmaceuticals has hired Najat Khan, Ph.D., as chief commercial officer and head of R&D. She joins from Johnson & Johnson where she was chief data science officer ...
Several stocks on the market offer investors the opportunity to capitalize on the rapidly growing field of artificial intelligence (AI). The list includes some of the "Magnificent Seven" stocks, as ...
Artificial intelligence (AI) has the potential to transform all sectors and industries throughout the economy. Investing in companies that are involved in this transformation can potentially result in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results